<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk is enhanced in certain <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> such as <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The reason for this accelerated process is likely to be multifactorial </plain></SENT>
<SENT sid="2" pm="."><plain>Traditional risk factors are more prevalent in some of these patient groups compared with the general population (e.g. smoking in RA and <z:hpo ids='HP_0000822'>hypertension</z:hpo> in SLE) </plain></SENT>
<SENT sid="3" pm="."><plain>However, these factors do not fully explain that enhanced risk </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> associated with these disorders as well as some specific autoantibodies have been shown to contribute to this increased risk although their role remains controversial </plain></SENT>
<SENT sid="5" pm="."><plain>The role of therapies is unclear and while steroids may exacerbate metabolic risk factors, the anti-inflammatory effects of traditional and more novel biological therapies may reduce overall cardiovascular risk in these populations </plain></SENT>
<SENT sid="6" pm="."><plain>We recommend proactive screening for modifiable <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in patients with these conditions </plain></SENT>
</text></document>